

TABLE OF CONTENTS

ABSTRACT	I
ZUSAMMENFASSUNG	III
ABBREVIATIONS	VI
TABLE OF FIGURES	VII
LIST OF TABLES	VIII
1 INTRODUCTION	1
1.1 THE LIVER	1
1.1.1 STRUCTURE OF THE LIVER	1
1.1.2 HEPATIC BIOTRANSFORMATION	3
1.2 PYRROLIZIDINE ALKALOIDS	5
1.2.1 OCCURRENCE AND HUMAN EXPOSURE	5
1.2.2 CHEMICAL STRUCTURE	7
1.2.3 TOXICOKINETICS	8
1.2.3.1 ABSORPTION, DISTRIBUTION AND EXCRETION	8
1.2.3.2 METABOLISM	9
1.2.4 TOXICITY	12
1.2.5 RISK ASSESSMENT OF PA	14
2 OBJECTIVE	16

3 CUMULATIVE PART: SUMMARY OF RESULTS	17
3.1 PUBLICATION I	17
HUMAN CYP3A4-MEDIATED TOXIFICATION OF THE PYRROLIZIDINE ALKALOID LASIOCARPINE	
3.2 PUBLICATION II	18
PYRROLIZIDINE ALKALOID-INDUCED ALTERATIONS OF PROSTANOID SYNTHESIS IN HUMAN ENDOTHELIAL CELLS	
3.3 PUBLICATION III	18
SENSITIZATION OF HUMAN LIVER CELLS TOWARD FAS-MEDIATED APOPTOSIS BY THE METABOLICALLY ACTIVATED PYRROLIZIDINE ALKALOID LASIOCARPINE	
4 SUMMARIZING DISCUSSION	20
5 FUTURE PERSPECTIVES	26
6 REFERENCES	29
7 PUBLICATIONS	37
7.1 PUBLICATION I	37
HUMAN CYP3A4-MEDIATED TOXIFICATION OF THE PYRROLIZIDINE ALKALOID LASIOCARPINE	
7.2 PUBLICATION II	57
PYRROLIZIDINE ALKALOID-INDUCED ALTERATIONS OF PROSTANOID SYNTHESIS IN HUMAN ENDOTHELIAL CELLS	
7.3 PUBLICATION III	76
SENSITIZATION OF HUMAN LIVER CELLS TOWARD FAS-MEDIATED APOPTOSIS BY THE METABOLICALLY ACTIVATED PYRROLIZIDINE ALKALOID LASIOCARPINE	
CONGRESS CONTRIBUTIONS	95
ACKNOWLEDGMENTS	96